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Abstract
Introduction. Preeclampsia is a formidable disease of the second half of pregnancy, leading to severe complications, 
including disability and even death. Many authors have recognized the correlation between the severity of preeclampsia 
and the degree of disturbances in the hemostasis system. In this regard, the objective of this study was to assess inhibi-
tion of platelet aggregation and the possibility of its correction with resverаtrol and nicorandil.
Materials and methods. The study was performed on 250 mature white Wistar female rats weighing 250–300  g. 
The platelet aggregation induced by ADP, collagen, ristomycin, adrenaline was determined, as well as PTT, TT, aPTT, 
fibrinogen, and the clotting time.
Results and discussion. Introduction of resverаtrol and nicorandil resulted in a decrease in thrombocyte aggregation 
capacity from 53.8 ± 2.60% to 22.1 ± 1.25% and 37.1 ± 1.79%, respectively, when using ADP as an inducer. The clot-
ting time was from 841 ± 42 s up to 1135 ± 33 s and 1034 ± 26 s, respectively. In addition, there was an increase in 
temporal parameters of plasma-coagulation hemostasis and a decrease in plasma fibrinogen content. The use of gliben-
clamide resulted in partial cancellation of the positive effects of resverаtrol and nicorandil, with an increase in platelet 
aggregation to 28.9 ± 1.8% and 43.9 ± 1.2% when using ADP as an inducer and a decrease in the thrombosis time to 
988 ± 26 s and 950 ± 22 s, respectively.
Conclusion. In animals with experimental preeclampsia, there were disturbances in the hemostasis system, comparable 
to those in the clinical situation. The use of resverаtrol and nicorandil leads to a pronounced correction of hemostasis 
parameters. The positive effects of the studied pharmacological agents are mediated by several mechanisms, including 
K+ATP channels.
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Introduction
Preeclampsia remains an urgent problem of modern me-
dicine and is one of the most ominous complications of 
pregnancy and childbirth (Gureev et al. 2014, Rezniko-
va 2013, Shuvalova et al. 2014). Preeclampsia is among 
the top three causes of maternal and perinatal mortality 
(Ministry of Healthcare of the RF 2016, Shuvalova et al. 
2014). Its incidence in recent years has tended to increase 
(Ministry of Healthcare of the Russian Federation 2016, 
Reznikova 2013, Shuvalova et al. 2014).
A large number of authors recognize endothelial dys-
function (Sánchez-Aranguren et al. 2014, Scioscia et al. 
2015) and placental ischemia caused by dysangiogenesis 
as the main elements of gestosis pathogenesis (Pereira et 
al. 2015, Ducray et al. 2011, Verlohren et al. 2010). Incom-
plete invasion of cytotrophoblast into the spiral arteries of 
the mother and their remaining constriction capacity leads 
to trophoblast ischemia and an increased permeability of 
the fetoplacental barrier (Ducray et al. 2011, van Oppen-
raaij et al. 2011, Wang et al. 2015). At the end of complex 
pathogenetic processes of the response with the release of 
a large number of humoral factors are an increase in the 
content of ADMA (asymmetric dimethylargenine), endo-
thelial dysfunction, secondary ischemic lesions, impaired 
hemostasis and oxidative stress (Gureev et al. 2014, Sán-
chez-Aranguren et al. 2014).
Disorders in the hemostasis system lead to severe com-
plications in obstetrics: DIC-syndrome, HELLP-syndrome 
and uterine bleeding in various stages. The hemostasis sys-
tem includes a vascular-thrombocytic unit, which consists 
of endothelium and platelets, and a plasma-coagulation 
unit, which consists of the blood coagulation system, the 
blood anticoagulation system and the fibrinolytic system.
In women with preeclampsia, on the surface of the pla-
telet, the expression of collagen receptors, von Willebrand 
factor, P-selectin significantly increases compared with 
normal pregnancy. This leads to an increased platelet ag-
gregation activity in preeclampsia (Holthe et al. 2004). In 
women with spontaneous premature labor, a failure of the 
physiological transformation of the spiral arteries and an 
abnormal angiogenic-antiangiogenic state of plasma were 
detected, comparable to such in women with preeclamp-
sia. The use of antiplatelet agents reduced spontaneous 
premature delivery in pregnant women at risk for deve-
loping pre-eclampsia (Kazmi et al. 2011, van Vliet et al. 
2017). The use of acetylsalicylic acid in low doses reduces 
the possibility of pre-eclampsia in pregnant women with 
high risk pregnancies (Käehne  and Lundin 2017, Mone et 
al. 2017, Sahin et al. 2015, Sarma and Scott 2016). Simu-
lation of preeclampsia in the experiment and its correction 
are also accompanied by a disturbed platelet aggregation 
ability and its normalization, respectively (Bariani et al. 
2017, Tyurenkov et al. 2012, Tyurenkov et al. 2014).
Due to the severity of the complications caused by 
impaired hemostasis in preeclampsia, as well as in con-
nection with the prevailing stereotype, abnormal plate-
let function has traditionally been considered within the 
hemostatic system (Blomqvist et al. 2018, Burke et al. 
2013, Burke et al. 2016). This is clearly seen even when 
trying to assess the severity of preeclampsia and other 
pathological conditions of pregnant women by impair-
ment of their function (Burke et al. 2016, Holthe et al 
2004, Sidorenko et al. 2007). But even the available data 
show contradictions in the results obtained by different 
authors. However, most authors claim a decrease in the 
activity of the coagulation system, platelet aggregation 
ability in early pregnancy, followed by their significant 
increase in childbirth and in the postnatal period, which 
looks logical (Blomqvist et al. 2018, Burke et al. 2013, 
Freitas et al. 2014, Hayashi et al. 1999, Hellgren 2003). 
In the third trimester, the platelet aggregation sensiti-
vity to ADP, adrenaline, ristomycin, collagen and other 
inducers increases (Blomqvist et al. 2018). This can be 
explained by increased expression of receptors for colla-
gen, von Willebrand factor, P-selectin and other factors 
that contribute to the aggregation on the surface of the 
platelet (Holthe et al. 2004).
There have only been a small number of scientific 
publications written recently which discuss a certain in-
dependent role of platelets in the development of pree-
clampsia and the possibility of preventing and treating 
placental-mediated complications with drugs correcting 
the function of platelets (Blomqvist et al. 2018, Holthe et 
al. 2004, van Vliet et al. 2017).
However, at the present stage, there is enough infor-
mation to consider the impaired platelet function as an 
independent key link in the pathogenesis of preeclampsia 
resulting in placental ischemia and a local endothelial dys-
function to its generalized form – systemic endotheliosis.
In this regard, the search for new drugs with a combin-
ed mechanism of action for the prevention and treatment 
of preeclampsia seems promising.
Earlier in our laboratory, the endothelioprotective 
properties of resverаtrol and nicorandil were investigated 
(Kochkarov 2009, Stupakova et al. 2018), which can acti-
vate K+ATP channels ( Novaković et al. 2015, Tanaka et al. 
2010), therefore they were considered to be the most pro-
mising for carrying out the present research. In addition, 
when they were used, a pronounced effect was observed 
when correcting morphofunctional disorders under con-
ditions of ADMA-like preeclampsia (Ivanets et al. 2015).
Objective: to conduct a study of platelet aggregation 
capacity in the condition of experimental preeclampsia 
and the possibility of its correction with resverаtrol and 
nicorandil.
Materials and methods
Complying with the ethical and regulatory require-
ments when doing research
The experimental part of the study was performed at the 
premises of the vivarium of Kursk State Medical University.
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The work was organized and carried out in compliance 
with the following regulatory acts and guidelines govern-
ing the conduct of experimental research in the Russian 
Federation:
1. Order of the Ministry of Healthcare of the Russia of 
April 1, 2016 No. 199N ”On Approval of the Rules of 
Good Laboratory Practice” (Order of the Ministry of 
Healthcare of the Russia 2016).
2. GOST 33044-2014 “Principles of Good Laboratory 
Practice” (GOST 2015).
3. GOST 33217-2014 “Guidelines for the Maintenance 
and Care of Laboratory Animals. Rules for the Main-
tenance and Care of Laboratory Predatory Mammals” 
(GOST 2016).
4. “Guidelines for Conducting Preclinical Studies of New 
Drugs”, Ed. Mironov A.N., - M.: Grif and Co. – 2012 
(Mironov 2012).
5. The ethical principles of treating laboratory animals 
were in compliance with “The European Convention 
for the Protection of Vertebral Animals Used for Expe-
rience and Other Scientific Purposes. CETS No. 123” 
(European Treaty Series 1986).
Experimental animals
The experiment was performed on 250 white Wistar fe-
male rats weighing 250-300 g. To form groups of preg-
nant animals with predetermined periods, the males (2 
animals) were introduced to the females, which had been 
kept separately, for 24 hours. Then the animals were sepa-
rated, and 10 days later, during the ether sleep, pregnancy 
was determined by palpation. In the experiments, preg-
nancy occurred in 30-40% of cases. ADMA-like agent 
– non-selective blocker NO-synthase N-nitro-L-argini-
ne-methyl ether (L-NAME) – was administered intraperi-
toneally at a dose of 25 mg/kg/day for seven days (14-20th 
days of pregnancy) (Gureev et al. 2014).
Determination of coagulation indicators and a degree 
of thrombocyte aggregation was performed on the 21st 
day of gestation. Blood from the abdominal aorta was 
collected into a test tube with a 3.8% solution of sodi-
um citrate in a ratio of 9:1, followed by centrifugation of 
1000 rpm for 10 minutes. Antiplatelet activity was deter-
mined by G.Born’s method modified by Z.A. Gabbasova 
et al. (1989) on a two-channel laser analyzer of platelet 
aggregation ALAT-2 (Biola). ADF (at a final concentra-
tion of 5 μM), collagen (50 μg/ml), ristomycin (5 μM), 
adrenaline (10 μM) were used as inducers (manufactured 
by SPD RENAM, Russia). Analysis was performed no 
later than 2 hours after obtaining blood. Coagulation in-
dicators were determined on a Start 4 (Diagnostica Stago, 
France) analyzer using reagents for the determination of 
prothrombin time (PTT), thrombin time (TT), activated 
partial thromboplastin time (aPTT), fibrinogen test (ma-
nufactured by SIEMENS). Thrombus formation time was 
determined on the 20th day of pregnancy in anesthetized 
(300 mg/kg of chloral hydrate) female rats with experi-
mental preeclampsia. Thrombus formation was caused by 
applying a 50% solution of iron (III) chloride, for which 
an area of the exposed carotid artery was isolated from 
the surrounding tissues, and a cotton pad moistened with 
a 50% solution of iron chloride (0.025 ml) was placed on 
it. The blood flow was recorded above the site of appli-
cation, using a Doppler probe (Minimax-Doppler-K, St. 
Petersburg). The time of blood clot formation from the 
moment of application of the iron (III) chloride solution 
to the complete cessation of blood flow in the carotid arte-
ry was noted (Karamysheva 2014, Voronkov 2011).
Descriptive statistics were applied to all the data: the 
data was checked for normal distribution. The type of dis-
tribution was determined by the Shapiro-Wilk criterion. In 
case of normal distribution, the mean value (M) and stan-
dard error of the mean (m) were calculated. Intergroup 
differences were analyzed by parametric (Student’s t-test) 
or non-parametric (Mann-Whitney test) methods, depen-
ding on the type of distribution. The statistical significan-
ce of the differences between the morphological changes 
after their ranking was assessed using the Mann-Whitney 
method for analyzing non-parametric data (Glants 1999, 
Sidorenko 2003). All calculations were performed using 
the Microsoft Excel 7.0. statistical package.
According to the objective of the study, all the animals 
were divided into the following groups:
1. Intact – pregnant + 0.9% NaCl from the 14th to the 20th 
days of pregnancy.
2. Control (L-NAME) – pregnant + ADMA-like agent 
(with intraperitoneal administration of L-NAME at a 
dose of 25 mg/kg once a day from the 14th to the 20th 
days of pregnancy).
3. Pregnant + L-NAME 25 mg/kg + Amlodipine (0.5 mg/
kg/day orally).
4. Pregnant + L-NAME 25 mg/kg + Nicorandil (2x10 
mg/kg/day orally).
5. Pregnant + L-NAME 25 mg/kg + Resverаtrol (2 mg/
kg/day orally).
6. Pregnant + L-NAME 25 mg/kg + Nicorandil (2x10 mg/
kg/day orally) + Amlodipine (0.5 mg/kg/day orally).
7. Pregnant + L-NAME 25 mg/kg + Resverаtrol (2 mg/
kg/day orally) + Amlodipine (0.5 mg/kg/day orally).
8. Pregnant + L-NAME 25 mg/kg + Nicorandil (2x10 
mg/kg/day orally) + Glibenclamide (50 mg/kg).
9. Pregnant + L-NAME 25 mg/kg + Resverаtrol (2 mg/
kg/day orally) + Glibenclamide (50 mg/kg).
Results and discussion
Modeling ADMA-like preeclampsia by intraperitoneal 
administration of L-NAME at a dose of 25 mg/kg/day 
resulted in an increase in platelet aggregation, which is 
evidenced by an increase in the maximum plasma light 
transmission (Fig. 1). When using ADF as an inducer, 
the light transmission increased from 24.3±1.09% to 
53.8±2.60%, when using collagen – from 50.2±1.66% to 
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81.3±2.68%, when using ristomycin – from 71.8±1.65% 
to 85.7±0.80% and when using adrenaline – from 
30.1±1.97% to 52.6±2.23%.
When administering the studied drugs, nicorandil and 
resverаtrol, to the animals with ADMA-like preeclamp-
sia, aggregation of platelets with individual peculiarities 
was corrected. The efficacy of both studied drugs excee-
ded the efficacy of the drug included in the standards of 
treatment of hypertensive states in pregnant women – am-
lodipine (Fig. 2).
When induced with ADP, collagen and adrenaline 
against the use of nicorandil, there was a statistically sig-
nificant decrease in platelet aggregation relative to that in 
the control (p<0.05), but it did not reach the target level 
and was statistically different from that in the group of 
intact animals (p<0.05). When inducing with ristomy-
cin, the platelet aggregation level was statistically lower 
(p<0.05) than that of the ”untreated” animals and reached 
the target level, as evidenced by there being no statistical 
difference from the platelet aggregation level of the ani-
mals of the intact group (Fig. 2).
The use of resveratrol resulted in the level of platelet 
aggregation induced with collagen, ristomycin, adrenaline 
being statistically lower than the level of induced platelet 
aggregation of the intact group (p<0.05). When inducing 
platelet aggregation with ADP against the background of 
applying resveratrol, the level was comparable to the le-
vel of induced aggregation of the group of intact animals.
The use of the studied drugs in conjunction with the drug 
that is included in the standards of treatment of hyperten-
sive states in pregnant women led to increased positive ef-
fects. Upon induction of platelet aggregation with collagen, 
ristomycin and adrenaline in animals with the combined 
use of nicorandil and amlodipine, there was a statistical-
ly significant (p<0.05) decrease in the level of aggregati-
on compared with that in monotherapy. Upon induction of 
platelet aggregation with adrenaline, aggregation reached a 
level comparable to the level of the group of intact animals. 
In the animals with a combined use of resverаtrol and am-
lodipine, there was a statistically significant (p<0.05) de-
crease, compared with that in monotherapy, in the level of 
platelet aggregation induced with ristomycin. At the same 
time, the induction level of platelet aggregation induced 
by ristomycin reached a statistically significant difference 
from the level of the group of intact animals (p<0.05).
The use of the studied drugs together with a K+ATP bloc-
ker channel glybenclamide led to partial cancellation of 
the positive effects (Fig. 3). Introduction of glibenclamide 
to animals with correction of ADMA-like preeclampsia 
with resverаtrol and nicorandil led to a statistically signi-
ficant increase in platelet aggregation by applying all the 
inducers used (p<0.05). At the same time, the level of in-
duced platelet aggregation remained significantly higher 
than that in the group of control animals.
The study of plasma-coagulation hemostasis revealed 
patterns that are similar in nature to changes in the previ-
A B
C D
Figure 1. Time of induced platelet aggregation when modeling ADMA-like preeclampsia. Note: A (ADP), B (Collagen), C (Risto-
mycin), D (Adrenaline) used as inducers; * – p<0.05 in comparison with L-NAME animals; y – p<0.05 in comparison with intact 
animals




Figure 2. The effect of nicorandil and resveratrol on the time of induced platelet aggregation in modeling ADMA-like preeclampsia. 
Note: A (ADP), B (Collagen), C (Ristomycin), D (Adrenaline) used as inducers; * – p<0.05 in comparison with L-NAME animals; 
y – p <0.05 in comparison with intact animals
ous experiments. When modeling ADMA-like preeclamp-
sia, the hemostasis system shifted to hypercoagulation, 
which is evidenced by an increase in plasma fibrinogen 
and a decrease in TT, PTT, and aPTT (p<0.05) (Table 1).
The use of the studied pharmacological agents resul-
ted in a statistically significant (p<0.05) correction of the 
parameters of plasma coagulation hemostasis, which was 
more pronounced than when using the reference drug am-
lodipine. In the groups using resverаtrol and nicorandil, 
the level of time indicators reached that in the group of 
intact animals. The content of fibrinogen was at the inter-
mediate level between the group of intact animals and the 
group of animals with ADMA-like preeclampsia and was 
statistically different from them (p<0.05).
The use of nicorandil and resverаtrol together with the 
drug which is included in the standards of treatment of 
hypertensive states in pregnant women led to an enhan-
cement of the corrective effects. Thus, in the group with 
the combined use of resverаtrol and amlodipine, the time 
indicators reached a statistically higher level compared to 
those of the intact animals. In the group of animals with 
the combined use of nicorandil and amlodipine, aPTT ex-
ceeded the level of the intact animals. In both groups with 
the combined use of the studied pharmacological agents 
and amlodipine, the fibrinogen content reduced to the le-
vel of the intact animals.
When using the studied pharmacological agents with 
glibenclamide to elucidate the mechanisms for correcting 
the hemostasis system, mediated through the activation of 
K+ATP channels, the data were obtained indicating a cer-
tain role of their activation in the positive effects from 
resverаtrol and nicorandil. In the group of animals with 
correction of ADMA-like preeclampsia with resveratrol, 
glibenclamide statistically significantly increased the 
time characteristics of plasma-coagulation hemostasis 
and plasma fibrinogen content (p<0.05). In the group of 
animals with the correction of ADMA-like preeclampsia 
with nicorandil, glibenclamide statistically significantly 
increased PTT (p<0.05), and TT reached the level that 
was statistically indistinguishable from that of the group 
of the ”untreated” animals.
In the next series of experiments, an analysis was car-
ried out of changes in the time of blood clot formation 
in the carotid artery, which in its essence was an integral 
sum of the states of the vascular-platelet and plasma-coa-
gulation components of hemostasis, as well as of their in-
teraction. Modeling ADMA-like preeclampsia resulted in 
a statistically significant (p<0.05) shortening of the time 
before cessation of blood flow in the carotid artery after 
applying FeCl3 1189±18 s to 841±42 s (Fig. 4).
The use of the studied pharmacological agents resulted 
in a statistically significant (p <0.05) lengthening of the 




Figure 3. Effects of glybenclamide on the time of induced platelet aggregation with the correction of an ADMA-like preeclampsia 
with nicorandil and resverаtrol. Note: A (ADP), B (Collagen), C (Ristomycin), D (Adrenaline) used as inducers; * – p<0.05 in 
comparison with L-NAME animals; y – p <0.05 in comparison with intact animals
Table 1. Indicators of Plasma-coagulation hemostasis during correction of ADMA-like Preeclampsia with Nicorandil and Res-
verаtrol (M ± m; N = 10)
Group TT, sec PTT, sec aPTT, sec Fibrinogen, g/L
Intact 24,3±1,6* 22,7±1,6* 17,8±0,8* 2,34±0,16*
L-NAME 15,3±1,6y 12,8±0,9y 10,3±0,6y 4,03±0,17y
Amlodipine 19,5±0,8*y 15,3±0,9y 11,0±0,6y 3,51±0,19*y
Resveratrol 26,8±1,5* 27,0±1,7* 19,2±0,9* 2,98±0,13*y
Nicorarandil 20,8±1,4* 20,0±1,0* 15,1±0,9* 3,23±0,08*y
Resveratrol + amlodipine 31,9±1,4*y 28,6±2,1*y 22,2±1,2*y 2,19±0,16*
Nicorandil + amlodipine 25,6±1,3* 25,8±1,3* 21,2±1,0*y 2,70±0,17*
Resveratrol + glibenclamide 20,7±1,7* 21,0±1,8* 15,5±1,2* 3,39±0,12*y
Nicorandil + glibenclamide 17,1±1,3y 16,1±1,2*y 13,8±1,0*y 3,62±0,11*y
Note: * – p<0.05 in comparison with L-NAME animals; y – p<0.05 in comparison with intact animals
thrombosis period to a level statistically indistinguishable 
from that in the group of intact animals with resverаtrol 
administration. Their use in conjunction with the drug, in-
cluded into the standard antihypertensive therapy in preg-
nant women, led to a greater lengthening of the time of 
thrombus formation with the greatest effect being observed 
in the group treated with nicorandil. In this group, the pe-
riod before the cessation of blood flow in the carotid artery 
reached a level statistically indistinguishable from those in 
the intact group and in the groups treated with resverаtrol.
As expected, based on the data from previous experi-
ments, the use of glibenclamide shortened the time requi-
red to complete blood clot formation, but it remained to 
be statistically longer than the time of blood clot formati-
on in groups of the “untreated” animals, which indicates 
an incomplete cancellation of the positive effects of the 
studied pharmacological agents.
Many aspects of the interaction of platelets and endot-
heliocytes in the pathogenesis of preeclampsia are still to 
be clarified, but joining them into a separate link within 
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the hemostasis emphasizes their close relationship. The 
triggering mechanism of the vascular-platelet hemostasis 
in case of damage to the vessel is the multi-stage acti-
vation of platelets when interacting with subendothelial 
layers. There is a change of the lipid composition of the 
surface layer of the membrane, an increased expression 
of receptors to adhesion molecules on the membrane sur-
face, Ca2+-dependent change in the thrombocyte shape; 
synthesis of thromboxane is initiated, as well as a release 
of humoral factors from platelet granules: ADP, serotonin, 
histamine, adrenalin, noradrenalin, dopamine, growth 
factors, factors regulating vascular wall permeability and 
chemotaxis of neutrophils and eosinophils and others 
promoting vasoconstriction, adhesion and aggregation of 
platelets (Kozlovsky et al. 2013, Lysenkov et al. 2004). 
At this stage, the reversible stage of platelet aggregation 
ends. The response of the endothelium is reduced forma-
tion of NO, prostacyclin and enhanced synthesis of en-
dothelin-1. As for functioning, a vasospasm is observed, 
which facilitates the adhesion of platelets.
Under natural conditions, when a vessel is damaged, 
activated platelets adhere on the subendothelial surface, 
in particular, collagen, and irreversible platelet aggrega-
tion occurs. Thus, activated platelets are used locally and 
hardly enter the systemic circulation.
With the development of preeclampsia, events occur 
in different conditions. It should be noted that platelet ac-
tivation can be caused not only by proteins of subendot-
helial structures, but also by adrenaline, norepinephrine, 
ADP, immune complexes, peroxide radicals, hypoxia, 
arterial hypertension, prostaglandins PgG2 and PgH2, 
arachidonic acid, thromboxane A2, platelet activating 
factor (PAF), phorbol esters, latex, lectins, A23187 ion-
ophore, bacteria and bacterial lipopolysaccharide, tumor 
cells, increased shear stress, etc. (Blomqvist et al. 2018, 
Kozlovsky et al. 2013, Lysenkov et al. 2004, Sidorenko 
et al. 2007). It is ischemic placenta that excretes a large 
number of these humoral factors, which leads to platelet 
activation. Depending on the inducers and their combi-
nation, the activation of platelets, as well as the humoral 
factors secreted by them and their ratios are of a diffe-
rent nature. Unlike natural conditions, there is no expo-
sed subendothelial layer, nor is there platelet adhesion at 
the site of activation. The mass of activated platelets goes 
into the systemic circulation, and it can be said that there 
is a kind of endocrine gland, located throughout the cir-
culating blood and directly contacting with endothelium. 
Therefore, even if the action of each individual platelet 
is considered locally, their mass location determines the 
generalization of their effects. When passing through the 
ischemic placenta, more and more new platelets are ac-
tivated. When a critical number is reached, the level of 
humoral factors secreted by platelets becomes sufficient 
to cause systemic endotheliosis. There is even a parallel 
between the DIC-syndrome, systemic inflammatory res-
ponse syndrome and preeclampsia (Lysenkov et al. 2004).
One of the diagnostic criteria for the severity of pree-
clampsia is the sFlt-1/PlGF ratio (Baranovskaya 2018, 
Ivanets et al. 2012, Ivanets et al. 2013, Ivanets et al. 2015). 
sFlt-1 is a variant of the vascular endothelial growth factor 
receptor (VEGFR-1). The higher this ratio, the higher the 
risk of preeclampsia or its severity. The source of sFlt-1 is 
not only an ischemic placenta, but also a platelet-monoci-
ne complex, which is obtained as a result of aggregation 
of platelet-activated monocyte (Major et al. 2014).
During pregnancy, platelet sensitivity to adrenaline, 
collagen, ristomycin, and other factors increases. This 
accurately determines polyetiology and another point of 
application of provoking factors in the pathogenesis of 
preeclampsia in such conditions as: infections, psychoe-
motional stress, conditions accompanied by excessive 
formation of peroxide radicals, metabolic syndrome, con-
Figure 4. The time of formation of a blood clot in the carotid artery when correcting ADMA-like preeclampsia with nicorandil and 
resverаtrol. Note: * – p<0.05 in comparison with L-NAME animals; y – p<0.05 in comparison with intact animals
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ditions accompanied by an increased content of ADMA 
and homocysteine, etc. (Karamysheva 2014, Lysenkov et 
al. 2004, Rudzevich 2011).
Thus, platelet activation is an intermediate patho-
genetic link between the immaturity of the spiral arte-
ries, ischemia of the placenta and systemic endothelial 
dysfunction. The chain of events described above looks 
logical in other pathological conditions as well, such as: 
sepsis, atherosclerosis, arterial hypertension, metabolic 
syndrome, varicose veins, etc. Summarizing the analyzed 
data, it can be said with a certain degree of accuracy that 
vascular-coagulation-immunological disorders in preg-
nant women have a common pathogenetic interaction in 
various diseases and, depending on the provoking factors 
and individual characteristics, determine the development 
of DIC-syndrome, preeclampsia or eclampsia.
An increase in platelet aggregation capacity and ac-
tivation of the plasma-coagulation component of he-
mostasis in modeling ADMA-like preeclampsia repeat 
the patterns observed in the clinic in women with pree-
clampsia. L-NAME is an analogue of ADMA, which, in 
turn, is an eNOS inhibitor. Therefore, the introduction of 
L-NAME results in a reduced activity of eNOS ,, as well 
as a reduced formation of potent antiaggregants – NO – 
by endothelium. At this stage, the most sensitive are the 
placental vessels. The resulting endothelial dysfunction 
leads to ischemic events in it. When passing through the 
placenta, platelets get activated due to ischemia, as well 
as due to humoral factors released in response. Activated 
platelets not only have an increased aggregation capaci-
ty by themselves, but also activate intact platelets, se-
creting aggregation inducers into the bloodstream. Mo-
deling ADMA-like preeclampsia leads to a pronounced 
persistent increase in blood pressure. There is a change 
in shear rate, which can also activate platelets. Accor-
ding to the literature, in women with preeclampsia, on 
the surface of the platelet, the expression of receptors 
to different aggregation inducers increases compared 
with that in normal pregnancy. This contributes to in-
creased sensitivity of platelets in them. No concrete li-
terature data on the number of receptors for aggregation 
inducers in animals with ADMA-like preeclampsia have 
been found, but taking into account the comparable pa-
thogenetic mechanisms of both pathological conditions, 
the probability of this mechanism is rather high.
The time of the blood clot formation until the complete 
cessation of blood flow in the artery is an integral sum of 
vascular-platelet and plasma-coagulation components of 
hemostasis. Therefore, its shortening is a logical conse-
quence of a shift of hemostasis towards hypercoagulation.
The pronounced positive effects of resveratrol in the 
correction of platelet aggregation disorders caused by 
the ADMA-like preeclampsia model are accounted for 
by several direct and indirect mechanisms. The literature 
describes various positive effects of resveratrol: improve-
ment of mitochondrial respiration, improvement of meta-
bolic processes in obesity and obesity-associated disea-
ses, anti-inflammatory effect, suppression of the growth 
of cancer cells, numerous positive effects in diseases of 
the cardiovascular system (Bitterman and Chung 2015).
As applied to the topic touched upon in this paper, the 
following studies deserve special attention. It was found 
that resveratrol inhibits PDE (Takizawa et al. 2015), in-
cluding PDE1 and PDE4 (Wang et al. 2016, Rauf et al. 
2017). These features explain the neuroprotective proper-
ties of resveratrol in ischemia (Wan et al. 2016). Inhibition 
of PDE3 explains the enhancement of myocardial con-
tractility without an arrhythmogenic effect. Reducing the 
expression of mRNA of most of the 11 PDE isoenzymes, 
including PDE3B, PDE8A and PDE10A, which are associ-
ated with the regulation of insulin secretion, resveratrol is 
capable of improving the function of β-cells of the pancreas 
in a dose-dependent way (Rouse et al. 2014). Resveratrol 
has a positive effect in erectile dysfunction in patients tole-
rant to PDE5 inhibitors. This effect is independent of eNOS 
mechanisms, is associated with the formation of hydrogen 
sulfide, and can also be endothelium-mediated (Dalakliog-
lu and Ozbey 2013, Yetik-Anacak et al. 2015). When res-
veratrol and sildenafil are used in animals to correct erectile 
dysfunction caused by streptozotocin diabetes, synergism 
is observed due to the effect on the NO-mediated signa-
ling pathway (Bai and An 2015). Antiplatelet properties of 
resveratrol are described in (Bonechi et al. 2017, Sun et al. 
2018). Resveratrol reduces the risk of thrombosis in expe-
rimental liver cirrhosis, normalizing platelet function (Xu 
et al. 2016). Resveratrol has pronounced positive effects in 
preeclampsia in humans and in experiment (Tenório et al. 
2018, Bariani et al. 2017, Ivanets et al. 2015). The ability 
of resveratrol under experimental conditions to reduce in-
flammation induced by lipopolysaccharides, and to prevent 
preterm labor was found in (Bariani et al. 2017).
When K+ATP channels are activated by resveratrol, cyto-
protective mechanisms of pharmacological preconditio-
ning are triggered. In addition, activation of K+ATP channels 
leads to a decrease in myometrial tone and improvement of 
microcirculation in the tissues of the placenta. Triggering 
pharmacological preconditioning and improving the micro-
circulation in the placenta lead to a decrease in the number 
of ischemic events in it, and consequently, the activation 
of platelets passing through it decreases. The fact that res-
veratrol has endothelium protective properties encourages 
the normalization of endothelium function and leads to the 
restoration of NO synthesis, lower blood pressure and also 
contributes to the improvement of microcirculation in the 
placenta with all logical consequences. Due to its direct ac-
tion, resveratrol can inhibit PDE3 and PDE5 in the platelet 
(Kleppe et al. 2018, Rauf et al. 2017, Takizawa et al. 2015, 
Wang et al. 2016). This leads to the accumulation of cyclic 
monophosphates inside the platelet, prevents the release of 
calcium from the depot and prevents the activation of the 
platelet or puts it in an inactive state.
The pronounced positive effects of nicoradil in the 
correction of platelet aggregation disorders caused by 
an ADMA-like model of preeclampsia are also associa-
ted with direct and mediated mechanisms. The literature 
also describes the positive effects of nicorandil in preg-
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nant women (Rezk et al. 2015), in particular, its ability 
to reduce platelet aggregation, including not through the 
Ca2+-dependent mechanism (Ivanova et al 1993).
By activating the K+ATP-channels, nicorandil, like res-
verаtrol, reduces ischemic effects in the placenta, triggering 
pharmacological preconditioning mechanisms and impro-
ving microcirculation in it. Endothelioprotective effects of 
nicorandil help reduce the factors that bring platelets into 
an activated form, reducing blood pressure and restoring 
the NO-synthesizing function of the endothelium similar to 
preeclampsia in ADMA. The direct mode of action of ni-
corandil shows in its ability to be an NO-donator, which in 
itself is a potnet factor preventing platelet aggregation, as 
well as to reduce platelet aggregation, including not through 
a Ca2+-dependent mechanism (Ivanova et al. 1993).
The enhancement of the positive effects of resverаtrol 
and nicorandil by means of a drug that is included in the 
standards of treatment of hypertensive states in pregnant 
women, amlodipine, is explained by its ability to enhance 
the positive effects of the studied pharmacological agents 
in correcting morphofunctional disorders in animals with 
ADMA-like preeclampsia and, thus, to a greater extent, 
lead to a decrease in the number of factors promoting the 
transition of platelets into the activated form.
Lengthening the time of thrombosis when using the 
studied pharmacological agents, as well as their combin-
ed use with the drug which is included in the standards 
of treatment of hypertensive states in pregnant women, 
is a logical consequence of the protective effects and re-
flects the patterns of changes in vascular-platelet and plas-
ma-coagulation components of hemostasis.
The incomplete cancellation of the positive effects of 
resverаtrol and nicorandil when they are used against the 
background of a K+ATP-channel blocker, glibenclamide, 
indicates their significant role in realizing the positive ef-
fects of the studied pharmacological agents. On the other 
hand, this indicates that resverаtrol and nicorandil have a 
complex mode of action, in which of great importance are 
the mechanisms that are not mediated by K+ATP-channels. 
This is also proved by the dynamics of the time of blood 
clot formation until the complete cessation of blood flow 
in the arteries.
Conclusion
When modeling ADMA-like preeclampsia, there is an in-
crease in platelet aggregation from about 19% to 121% 
when the inducers used are ADP, collagen, ristomycin and 
adrenaline, as well as a shift in the plasma-coagulation 
component of hemostasis towards hypercoagulation. The 
time of blood clot formation was reduced to 70% of the 
original. The use of resverаtrol and nicorandil resulted 
in a pronounced correction of the disturbance of induced 
platelet aggregation, indicators of the plasma-coagulation 
component of hemostasis and the time of thrombus for-
mation. A significant part of the positive effects of res-
verаtrol and nicorandil in the correction of hemostatic 
disorders in animals with ADMA-like preeclampsia are 
mediated by K+ATP-channels.
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